EE04199B1 - Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamine - Google Patents

Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamine

Info

Publication number
EE04199B1
EE04199B1 EE9700344A EE9700344A EE04199B1 EE 04199 B1 EE04199 B1 EE 04199B1 EE 9700344 A EE9700344 A EE 9700344A EE 9700344 A EE9700344 A EE 9700344A EE 04199 B1 EE04199 B1 EE 04199B1
Authority
EE
Estonia
Prior art keywords
recombinant mva
vaccine
eukaryotic cell
mva virus
isolated eukaryotic
Prior art date
Application number
EE9700344A
Other languages
English (en)
Estonian (et)
Other versions
EE9700344A (et
Inventor
Sutter Gerd
Ohlmann Marion
Erfle Volker
Original Assignee
GSF-Forschungszentrum f�r Umwelt und Gesundheit GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8097499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04199(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GSF-Forschungszentrum f�r Umwelt und Gesundheit GmbH filed Critical GSF-Forschungszentrum f�r Umwelt und Gesundheit GmbH
Publication of EE9700344A publication Critical patent/EE9700344A/xx
Publication of EE04199B1 publication Critical patent/EE04199B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Manufacturing & Machinery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EE9700344A 1995-07-04 1996-07-03 Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamine EE04199B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK78295 1995-07-04
PCT/EP1996/002926 WO1997002355A1 (en) 1995-07-04 1996-07-03 Recombinant mva virus, and the use thereof

Publications (2)

Publication Number Publication Date
EE9700344A EE9700344A (et) 1998-06-15
EE04199B1 true EE04199B1 (et) 2003-12-15

Family

ID=8097499

Family Applications (3)

Application Number Title Priority Date Filing Date
EEP200300331A EE05138B1 (et) 1995-07-04 1996-07-03 Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin
EE9700344A EE04199B1 (et) 1995-07-04 1996-07-03 Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamine
EEP200300332A EE04753B1 (et) 1995-07-04 1996-07-03 Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EEP200300331A EE05138B1 (et) 1995-07-04 1996-07-03 Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin

Family Applications After (1)

Application Number Title Priority Date Filing Date
EEP200300332A EE04753B1 (et) 1995-07-04 1996-07-03 Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin

Country Status (27)

Country Link
US (6) US6440422B1 (xx)
EP (3) EP0836648B1 (xx)
JP (3) JP4312260B2 (xx)
KR (1) KR19990028617A (xx)
CN (3) CN1154742C (xx)
AT (3) ATE304058T1 (xx)
AU (1) AU721735B2 (xx)
BR (1) BR9609303B8 (xx)
CA (3) CA2225278C (xx)
CZ (1) CZ292460B6 (xx)
DE (3) DE69635172T2 (xx)
DK (3) DK1312678T3 (xx)
EE (3) EE05138B1 (xx)
ES (3) ES2249647T3 (xx)
HK (2) HK1009830A1 (xx)
HU (2) HU224061B1 (xx)
IL (5) IL122120A (xx)
MX (1) MX9800025A (xx)
NO (1) NO322476B1 (xx)
NZ (1) NZ313597A (xx)
PL (1) PL186857B1 (xx)
PT (1) PT836648E (xx)
RU (1) RU2198217C2 (xx)
SI (3) SI1312678T1 (xx)
TW (2) TW575664B (xx)
UA (3) UA68327C2 (xx)
WO (1) WO1997002355A1 (xx)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7118754B1 (en) * 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
ID19548A (id) * 1996-09-24 1998-07-23 Bavarian Nordic Res Inst As Virus mva rekombinan yang mengekspresikan antigen-antigen virus demam dan penggunaan daripadanya dalam vaksin-vaksin
MY119381A (en) * 1996-12-24 2005-05-31 Gsf Forschungszentrum Umwelt Recombinant mva virus, and the use thereof
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
FR2784997A1 (fr) * 1998-10-22 2000-04-28 Transgene Sa Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes
US20040265324A1 (en) * 1999-03-23 2004-12-30 Cardosa Mary Jane Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
WO2000073476A1 (en) * 1999-05-28 2000-12-07 Gsf Forschungszentrum Für Umwelt Und Gesundheit Gmbh Vector for integration of heterologous sequences into poxviral genomes
US20150231227A1 (en) * 2000-03-02 2015-08-20 Emory University Compositions and methods for generating an immune response
ES2249430T3 (es) * 2000-03-14 2006-04-01 Bavarian Nordic A/S Cepa alterada del virus ankara de la vacuna modificado (mva).
DE10042598A1 (de) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
AU2002211654A1 (en) * 2000-10-10 2002-04-22 Genstar Therapeutics Minimal adenoviral vector and recombinant vaccines based thereon
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
AU2002231639B2 (en) 2000-11-23 2007-01-04 Bavarian Nordic A/S Modified vaccinia ankara virus variant
US7740863B2 (en) 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
DE10144664B4 (de) * 2001-09-11 2005-06-09 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
AU2002356690B2 (en) 2001-12-04 2008-07-24 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
DK1407006T3 (da) * 2001-12-20 2005-12-12 Bavarian Nordic As Fremgangsmåde til indvinding og oprensning af poxvirus fra inficerede celler
EP1420822B2 (en) * 2002-04-19 2017-07-05 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
WO2003097846A1 (en) 2002-05-16 2003-11-27 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
DK1404852T3 (da) * 2002-05-16 2006-05-08 Bavarian Nordic As Ekspression af gener i modificeret vacciniavirus Ankara ved anvendelse af kokoppe-ATI-promotoren
KR101044538B1 (ko) 2002-09-05 2011-06-27 버베리안 노딕 에이/에스 무혈청 조건하에서 일차세포의 배양 및 바이러스의 증식방법
DE10249390A1 (de) * 2002-10-23 2004-05-13 Ruprecht-Karls-Universität Heidelberg Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
WO2004048582A2 (en) * 2002-11-25 2004-06-10 Bavarian Nordic A/S Recombinant poxvirus comprising at least two cowpox ati promoters
DK1594970T3 (da) * 2003-02-18 2008-11-17 Helmholtz Zentrum Muenchen Fremgangsmåde til generering af rekombinant MVA
EP1601333B1 (en) * 2003-02-20 2013-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Novel insertion sites in pox vectors
WO2004085659A2 (en) 2003-03-27 2004-10-07 Ottawa Health Research Institute Mutant vesicular stomatitis viruses and uses thereof
US7731974B2 (en) * 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
US7163685B2 (en) * 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
GB2402391A (en) * 2003-06-04 2004-12-08 Oxxon Pharmaccines Ltd Fowlpox recombinant genome
JP4842128B2 (ja) 2003-07-21 2011-12-21 トランジェーヌ、ソシエテ、アノニム 新規多機能性サイトカイン
US20100189747A1 (en) * 2003-07-31 2010-07-29 Raymond Weinstein Compositions and methods for treating or preventing hiv infection
EP1518932A1 (en) 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
ATE377088T1 (de) * 2003-11-24 2007-11-15 Bavarian Nordic As Promotoren zur expression in modifiziertem vaccinia virus ankara
JP4719855B2 (ja) 2003-12-05 2011-07-06 国立大学法人北海道大学 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター
EP1683870A1 (en) * 2005-01-24 2006-07-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vaccines based on the use of MVA
WO2006113927A2 (en) * 2005-04-20 2006-10-26 University Of Washington Immunogenic vaccinia peptides and methods of using same
US20090060947A1 (en) * 2006-05-19 2009-03-05 Sanofi Pasteur, Inc. Immunological compositions
RU2489486C2 (ru) * 2006-06-20 2013-08-10 Трансжене С.А. Процесс получения поксвирусов и композиции поксвирусов
US7972605B2 (en) * 2006-09-08 2011-07-05 Duke University Modified vaccinia ankara virus vaccine
CA2921048C (en) 2006-09-15 2018-06-05 Ottawa Hospital Research Institute Oncolytic rhabdovirus
AU2007307080B2 (en) 2006-10-06 2014-01-09 Bavarian Nordic A/S Methods for treating cancer with MVA
US20080241139A1 (en) * 2006-10-31 2008-10-02 Regents Of The University Of Colorado Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
WO2008094510A2 (en) * 2007-01-26 2008-08-07 The Regents Of The University Of Colorado Methods of modulating immune function
US20110159018A1 (en) 2007-05-03 2011-06-30 Medizinische Universitat Innsbruck Complement factor h-derived short consensus repeat-antibody constructs
US8003363B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
WO2008138533A1 (en) * 2007-05-14 2008-11-20 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US8003364B2 (en) * 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
US20100285050A1 (en) * 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
BRPI0800485B8 (pt) * 2008-01-17 2021-05-25 Univ Minas Gerais vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
WO2009100521A1 (en) 2008-02-12 2009-08-20 Sanofi Pasteur Limited Methods using ion exchange and gel filtration chromatography for poxvirus purification
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CA2760315C (en) 2009-04-30 2019-05-28 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Modified immunization vectors
KR20120052352A (ko) 2009-08-07 2012-05-23 트랜스진 에스.에이. Ｈｂｖ 감염을 치료하는 조성물
US9005632B2 (en) 2009-11-20 2015-04-14 Takeda Vaccines, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
CA2781397A1 (en) * 2009-11-20 2011-05-26 Inviragen, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
GB201006405D0 (en) * 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
WO2012101509A2 (en) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Immunological compositions against hiv
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CN103732236B (zh) 2011-08-05 2017-09-15 新罗杰公司 用于生产痘苗病毒的方法和组合物
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
CA2959867C (en) * 2011-09-26 2020-04-28 Theravectys Use of non-subtype b gag proteins for lentiviral packaging
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
SG11201500171YA (en) 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
EP3587455A1 (en) 2012-10-23 2020-01-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
US20140286981A1 (en) 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10765731B2 (en) 2014-01-09 2020-09-08 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
AU2015320574B2 (en) 2014-09-26 2018-12-06 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for inducing protective immunity against Human Immunodeficiency Virus infection
EP3244919A4 (en) 2015-01-12 2018-06-27 Geovax, Inc. Compositions and methods for generating an immune response to a hemorrhagic fever virus
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
MX2018007198A (es) 2015-12-15 2018-08-01 Janssen Vaccines & Prevention Bv Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
JP7150611B2 (ja) 2016-01-08 2022-10-11 ジオバックス・インコーポレイテッド 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法
BR112018015696A2 (pt) 2016-02-03 2018-12-26 Geovax Inc composições e métodos para gerar uma resposta imune para um flavivírus
CN109152827B (zh) * 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
MA45381A (fr) 2016-06-16 2021-04-21 Janssen Vaccines & Prevention Bv Formulation de vaccin contre le vih
AU2017318689A1 (en) 2016-09-02 2019-04-11 Beth Israel Deaconess Medical Center, Inc. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
MD3512543T2 (ro) 2016-09-15 2020-11-30 Janssen Vaccines & Prevention Bv Mutații de stabilizare a trimerului proteinei de înveliș HIV
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
BR112019026126A2 (pt) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
EP3641803A2 (en) 2017-06-21 2020-04-29 Transgene Personalized vaccine
WO2019016062A1 (en) 2017-07-19 2019-01-24 Janssen Vaccines & Prevention B.V. HIV ENVELOPE PROTEIN MUTATIONS STABILIZING TRIMERIC FORM
WO2019018724A1 (en) 2017-07-21 2019-01-24 Janssen Vaccines & Prevention B.V. METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
US20220118077A1 (en) 2018-09-11 2022-04-21 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
WO2020237052A1 (en) 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
CA3151982A1 (en) * 2019-10-16 2021-04-22 Stephen H. Thorne Producer viruses for generation of retroviruses in situ
CN116322757A (zh) 2019-11-14 2023-06-23 埃利克斯疗法公司 用于疫苗的剂量方案
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
TW202305125A (zh) 2021-04-30 2023-02-01 美商凱立凡爾免疫治療股份有限公司 用於經修飾mhc表現之溶瘤病毒
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
EP4358999A1 (en) 2021-06-23 2024-05-01 Consejo Superior De Investigaciones Científicas Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023220283A1 (en) 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Poxvirus adjuvant for t-cell vaccination
EP4316514A1 (en) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vectors and their use as vaccine against sars-cov-2

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
JPH0795954B2 (ja) 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
US5679511A (en) * 1986-10-06 1997-10-21 Donald Guthrie Foundation For Medical Research, Inc. CDNA clones for a regulatory protein in the melanin-production pathway
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5221610A (en) * 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
CN1042564A (zh) * 1988-11-11 1990-05-30 中国科学院上海生物化学研究所 乙肝疫苗的制备方法及其制品
JPH03271233A (ja) * 1990-03-19 1991-12-03 Inst Pasteur ウイルスエンベロープ糖タンパク質及びその糖タンパク質の中和エピトープに対応するペプチドの間の相乗作用による、ウイルス性感染に対する防御の誘発
WO1993008836A1 (en) 1991-10-28 1993-05-13 Institut Pasteur Induction of protection against viral infection by synergy between viral proteins and viral peptides
PT1025849E (pt) * 1992-12-22 2002-09-30 Ludwig Inst Cancer Res Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
EP0728764A4 (en) * 1993-10-19 1999-01-20 Ajinomoto Kk PEPTIDE THE IMMUNE RESPONSE TO HIV UNDUCED AND MEDICINAL PRODUCTS CONTAINING THE PREVENTION OR TREATMENT OF AIDS
US5676950A (en) * 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals

Also Published As

Publication number Publication date
DK0836648T3 (da) 2003-08-25
UA68327C2 (en) 2004-08-16
TW200305646A (en) 2003-11-01
CN1554764A (zh) 2004-12-15
DE69628011D1 (de) 2003-06-12
TWI245075B (en) 2005-12-11
DE69635172T2 (de) 2006-06-22
NZ313597A (en) 1999-01-28
BR9609303A (pt) 1999-05-25
EE05138B1 (et) 2009-02-16
PL324347A1 (en) 1998-05-25
HUP9802217A2 (hu) 1999-01-28
US20070071769A1 (en) 2007-03-29
US20100266630A1 (en) 2010-10-21
IL212933A0 (en) 2011-07-31
EP1312679B1 (en) 2005-09-07
JPH11509091A (ja) 1999-08-17
IL219528A0 (en) 2012-06-28
AU6611096A (en) 1997-02-05
ATE304057T1 (de) 2005-09-15
HU0402350D0 (en) 2005-01-28
ES2199294T3 (es) 2004-02-16
AU721735B2 (en) 2000-07-13
JP2007244382A (ja) 2007-09-27
BR9609303B8 (pt) 2014-05-06
EP0836648B1 (en) 2003-05-07
CN1189857A (zh) 1998-08-05
US20070071770A1 (en) 2007-03-29
CA2225278C (en) 2009-01-27
EE04753B1 (et) 2006-12-15
RU2198217C2 (ru) 2003-02-10
UA75410C2 (en) 2006-04-17
CZ424197A3 (cs) 1998-03-18
DK1312679T3 (da) 2006-01-09
US20030035792A1 (en) 2003-02-20
US8153138B2 (en) 2012-04-10
IL122120A (en) 2005-07-25
SI1312678T1 (sl) 2006-02-28
HK1009830A1 (en) 1999-06-11
HUP9802217A3 (en) 1999-09-28
DE69635172D1 (de) 2005-10-13
EP1312679A1 (en) 2003-05-21
US7198934B2 (en) 2007-04-03
JP4764367B2 (ja) 2011-08-31
NO980026L (no) 1998-01-02
CA2608864C (en) 2010-09-07
CN1554764B (zh) 2012-03-21
ES2249647T3 (es) 2006-04-01
IL164318A0 (en) 2005-12-18
PT836648E (pt) 2003-09-30
CA2225278A1 (en) 1997-01-23
ATE304058T1 (de) 2005-09-15
CA2608864A1 (en) 1997-01-23
CN1782071A (zh) 2006-06-07
EP0836648A1 (en) 1998-04-22
HU224061B1 (hu) 2005-05-30
US6440422B1 (en) 2002-08-27
IL164318A (en) 2013-08-29
DK1312678T3 (da) 2005-12-19
DE69635173T2 (de) 2006-07-13
DE69635173D1 (de) 2005-10-13
US20100291139A1 (en) 2010-11-18
ES2249648T3 (es) 2006-04-01
CA2596274A1 (en) 1997-01-23
TW575664B (en) 2004-02-11
SI1312679T1 (sl) 2006-02-28
EP1312679B8 (en) 2005-11-23
EP1312678A1 (en) 2003-05-21
JP2007252374A (ja) 2007-10-04
CN1154742C (zh) 2004-06-23
DE69628011T2 (de) 2004-03-18
ATE239796T1 (de) 2003-05-15
EE200300332A (et) 2003-10-15
WO1997002355A1 (en) 1997-01-23
IL122120A0 (en) 1998-04-05
UA75411C2 (en) 2006-04-17
SI0836648T1 (en) 2003-12-31
HU229261B1 (en) 2013-10-28
NO322476B1 (no) 2006-10-09
JP4312260B2 (ja) 2009-08-12
IL202448A0 (en) 2011-07-31
EP1312678B1 (en) 2005-09-07
CZ292460B6 (cs) 2003-09-17
HK1068015A1 (en) 2005-04-22
EE9700344A (et) 1998-06-15
EE200300331A (et) 2003-10-15
BR9609303B1 (pt) 2014-04-08
KR19990028617A (ko) 1999-04-15
NO980026D0 (no) 1998-01-02
US8197825B2 (en) 2012-06-12
MX9800025A (es) 1998-03-31
PL186857B1 (pl) 2004-03-31
CA2596274C (en) 2010-09-07
JP4764366B2 (ja) 2011-08-31

Similar Documents

Publication Publication Date Title
EE04199B1 (et) Rekombinantne MVA viirus, isoleeritud eukarüootnerakk ja vaktsiin ning nende kasutamine
DE69332831T2 (de) Rekombinanter schweinepocken-virus
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
HUP9802587A2 (hu) Glükózzal indukálható rekombináns virális vektor, ezt tartalmazó gyógyszerkészítmény és ezzel transzformált sejtek
MY134484A (en) Recombinant mva virus, and the use thereof
MY119381A (en) Recombinant mva virus, and the use thereof
MY157873A (en) Recombinant mva virus, and the use thereof

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231